NextBio Facilitates Additional Search Capabilities on Elsevier SciVerse Applications through Launch of Two New Applications

NextBio Facilitates Additional Search Capabilities on Elsevier SciVerse Applications through Launch of Two New Applications

CUPERTINO, CA: NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, announced the launch of two new applications on the Elsevier SciVerse platform. The new applications, reflecting the successful ongoing collaboration between NextBio and Elsevier, further demonstrate NextBio's capabilities for searching for relevant text in all types of content at the document, section, paragraph and sentence level. SciVerse is an innovative platform that integrates Elsevier's key products and encourages the scientific community to collaborate on the development of customized search and discovery applications.

The two new applications include:

 

  • SearchAssist: An application that leverages NextBio's auto-complete API and provides auto-complete suggestions composed of terms gathered from diseases, compounds, drugs, anatomy, organisms, genes, biogroups, SNPs (over 18 million), author names (over 6 million) and other biological concepts. It leverages a number of open ontologies including MeSH, Snomed CT, PubChem, DrugBank, and Gene Ontology.
  • Section Search application: An application that decomposes an article into eight sections: Title, Abstract, Introduction, Methods, Results, Discussion, Summary, and Captions. A user can search through one or more of these sections to retrieve articles of interest and further filter their results using faceted (Year, Journals, Authors, and Affiliations) navigation.

These new applications add to the three previous applications - Matching Sentences, Methods Search, and Prolific Authors - that NextBio launched on the Elsevier SciVerse platform in September 2010.

 

"This suite of NextBio applications on SciVerse demonstrates how NextBio technology and APIs can be leveraged to build a variety of useful applications," said Satnam Alag, NextBio Vice President of Engineering. "They also effectively demonstrate NextBio's capabilities for searching for relevant text at multiple levels within all types of content, not just content within the life and health sciences."

"The new applications furthermore show the power of our applications framework , by which technology companies and academic developers can leverage our APIs and our content to build new solutions that enhance the search and discovery experience of our users," said Rafael Sidi, Vice President, Application Marketplace and Developer Network, Elsevier.

"NextBio's expertise in text-based search, ontology management, and semantic enrichment of content also very nicely complements our company's own unique data search and correlations engine," said Saeid Akhtari, NextBio co-founder, President and Chief Executive Officer. "We have invested in building a comprehensive suite of APIs to enable our partners and customers to build their own applications, as illustrated by the SearchAssist application."

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively. For more information about SciVerse please visit http://www.info.sciverse.com/.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.